Literature DB >> 23406047

BRAF V600E inhibition in anaplastic thyroid cancer.

Michael H Rosove, Parvin F Peddi, John A Glaspy.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23406047     DOI: 10.1056/NEJMc1215697

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  75 in total

1.  Multimodality Treatment Improves Locoregional Control, Progression-Free and Overall Survival in Patients with Anaplastic Thyroid Cancer: A Retrospective Cohort Study Comparing Oncological Outcomes and Morbidity between Multimodality Treatment and Limited Treatment.

Authors:  Pascal K C Jonker; John Turchini; Schelto Kruijff; Jia Feng Lin; Anthony J Gill; Thomas Eade; Ahmad Ahniss; Roderick Clifton-Bligh; Diana Learoyd; Bruce Robinson; Venessa Tsang; Anthony Glover; Stanley Sidhu; Mark Sywak
Journal:  Ann Surg Oncol       Date:  2021-05-25       Impact factor: 5.344

2.  Anaplastic Thyroid Carcinoma, Version 2.2015.

Authors:  Robert I Haddad; William M Lydiatt; Douglas W Ball; Naifa Lamki Busaidy; David Byrd; Glenda Callender; Paxton Dickson; Quan-Yang Duh; Hormoz Ehya; Megan Haymart; Carl Hoh; Jason P Hunt; Andrei Iagaru; Fouad Kandeel; Peter Kopp; Dominick M Lamonica; Judith C McCaffrey; Jeffrey F Moley; Lee Parks; Christopher D Raeburn; John A Ridge; Matthew D Ringel; Randall P Scheri; Jatin P Shah; Robert C Smallridge; Cord Sturgeon; Thomas N Wang; Lori J Wirth; Karin G Hoffmann; Miranda Hughes
Journal:  J Natl Compr Canc Netw       Date:  2015-09       Impact factor: 11.908

3.  Akt inhibition enhances the cytotoxic effect of apigenin in combination with PLX4032 in anaplastic thyroid carcinoma cells harboring BRAFV600E.

Authors:  S H Kim; J G Kang; C S Kim; S H Ihm; M G Choi; H J Yoo; S J Lee
Journal:  J Endocrinol Invest       Date:  2013-09-27       Impact factor: 4.256

Review 4.  Translational research in endocrine surgery.

Authors:  Scott K Sherman; James R Howe
Journal:  Surg Oncol Clin N Am       Date:  2013-07-26       Impact factor: 3.495

5.  Role of BRAFV600E in the first preclinical model of multifocal infiltrating myopericytoma development and microenvironment.

Authors:  Peter M Sadow; Carmen Priolo; Simona Nanni; Florian A Karreth; Mark Duquette; Roberta Martinelli; Amjad Husain; John Clohessy; Heinz Kutzner; Thomas Mentzel; Christopher V Carman; Antonella Farsetti; Elizabeth Petri Henske; Emanuele Palescandolo; Laura E Macconaill; Seum Chung; Guido Fadda; Celestino Pio Lombardi; Antonina M De Angelis; Oreste Durante; John A Parker; Alfredo Pontecorvi; Harold F Dvorak; Christopher Fletcher; Pier Paolo Pandolfi; Jack Lawler; Carmelo Nucera
Journal:  J Natl Cancer Inst       Date:  2014-07-25       Impact factor: 13.506

6.  Use of vemurafenib in anaplastic thyroid carcinoma: a case report.

Authors:  Kristen A Marten; Vinay K Gudena
Journal:  Cancer Biol Ther       Date:  2015-07-15       Impact factor: 4.742

7.  Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer.

Authors:  Soeren Latteyer; Vera Tiedje; Katharina König; Saskia Ting; Lukas C Heukamp; Lydia Meder; Kurt Werner Schmid; Dagmar Führer; Lars Christian Moeller
Journal:  Endocrine       Date:  2016-10-01       Impact factor: 3.633

8.  Anaplastic thyroid carcinoma: changing trends of treatment strategies and associated overall survival.

Authors:  Sabine Wächter; C Vorländer; J Schabram; I Mintziras; I Fülber; J Manoharan; K Holzer; D K Bartsch; E Maurer
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-02-14       Impact factor: 2.503

9.  Vemurafenib may overcome TNF-related apoptosis-inducing ligand (TRAIL) resistance in anaplastic thyroid cancer cells.

Authors:  Tania Pilli; Silvia Cantara; Carlotta Marzocchi; Furio Pacini; Bellur S Prabhakar; Maria Grazia Castagna
Journal:  Endocrine       Date:  2019-08-03       Impact factor: 3.633

10.  BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment.

Authors:  Svetlana A Protsenko; Anna I Semionova; Yuri I Komarov; Svetlana N Aleksakhina; Alexandr O Ivantsov; Aglaya G Iyevleva; Evgeny N Imyanitov
Journal:  Invest New Drugs       Date:  2015-08-20       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.